#USA #H.I.G. Capital #Miami #Celerion #THL Partners

H.I.G. Capital Completes Sale of Celerion Holdings

On April 22, 2026, H.I.G. Capital, a prominent global investment firm with $74 billion under management, announced that it has signed a definitive agreement to sell Celerion Holdings, Inc. to funds affiliated with THL Partners. This strategic move reflects H.I.G.'s commitment to fostering growth and maximizing market opportunities for its portfolio companies.

About Celerion

Celerion, headquartered in Lincoln, Nebraska, stands out as a leading clinical research organization (CRO) specializing in clinical pharmacology and bioanalytical sciences. The company is renowned for its expertise in complex clinical pharmacology studies, including first-in-human dose escalation and drug-drug interaction assessments. With facilities located in Lincoln, Phoenix, Zurich, and Belfast, Celerion provides a comprehensive suite of services that assist pharmaceutical and biotechnology clients in navigating the intricate landscape of clinical trials.

Since its acquisition by H.I.G. in November 2022, Celerion has experienced remarkable growth, thanks to strategic investments aimed at enhancing its commercial, operational, and technological capabilities. These efforts have not only expanded Celerion’s laboratory footprint but also positioned the company more robustly within the competitive CRO landscape, enabling it to deliver first-rate services to its extensive global clientele.

Leadership Insights

Susan Thornton, President and CEO of Celerion, expressed gratitude towards H.I.G., stating that their partnership significantly accelerated vital strategic initiatives. The infused investments in Celerion's people, capabilities, and infrastructure have not only fortified its platform but also improved the quality of services delivered to clients. She added, “We are excited to carry this momentum forward with THL as we enter the next growth phase.”

H.I.G.'s Managing Director, Mike Gallagher, underscored the accomplishments made during their association with Celerion. He noted that the remarkable growth experienced underlines the dedication and skills of Celerion's team, positioning the company for continued success moving forward. At the same time, Managing Director Michael Kuritzky reflected on the valuable work Celerion undertakes to guide drug sponsors through the complexities of clinical trial management, highlighting the collaborative effort that has been pivotal to achieving current success.

Strategic Advisors

In connection with this transaction, BofA Securities, Inc. and Lazard Frères & Co. LLC served as financial advisors for H.I.G. and Celerion, while McDermott Will & Schulte LLP acted as legal counsel.

Celerion's Global Reach

Celerion provides extensive clinical trial solutions to pharmaceutical and biotechnology partners, performing studies across North America, Europe, and Asia. The company specializes in a variety of testing services, from first-in-human trials to proof-of-concept studies, accompanied by bioanalytical laboratory services and comprehensive data management solutions. With a reputation for excellence and a commitment to advancing clinical research, Celerion is poised to build upon the solid foundation created during its partnership with H.I.G., and now with THL Partners.

For further insights regarding Celerion and its capabilities, visit celerion.com.

H.I.G. Capital’s Vision

H.I.G. Capital, founded in 1993, has invested in over 400 companies globally, focusing primarily on middle-market businesses. By employing tailored strategies, H.I.G. aims not only to propel business growth but also to enhance value through an operationally focused approach. The firm is well-known for its flexible investments that include management buyouts, recapitalizations, and corporate carve-outs, showcasing a diverse portfolio that supports various sectors.

In summary, the strategic sale of Celerion marks another important milestone for H.I.G. Capital, as it continues to innovate and deliver growth-driven solutions amid a dynamic market landscape. With THL Partners at the helm, Celerion’s promising trajectory seems well-lit, as it prepares to embark on its latest growth chapter with renewed vigor and ambition.